TIDMOPTS
Optos plc
09 October 2013
OPTOS SECURES FIRST CORPORATE ACCOUNT ORDER FOR DAYTONA IN
UNITED STATES
HVHC, INC. AND VISIONWORKS ORDERS 100 DAYTONA
ULTRA-WIDEFIELD RETINAL IMAGING DEVICES
LONDON, UK, 9 October 2013 - Optos plc (LSE: OPTS), a leading
medical retinal imaging company, announces that it has agreed terms
to supply 100 Daytona ultra-widefield retinal imaging devices to
HVHC, Inc. for installation in its Visionworks' optometry stores in
the USA.
HVHC, Inc. is a leading provider of eye care services in the USA
with more than 600 Visionworks optical retail stores in 40 states
and the District of Columbia. The order for 100 Daytonas will be
delivered during the 12-month period commencing September 2013.
Roy Davis, CEO, commented: "We are delighted to announce this
important order with HVHC and Visionworks, a leading provider of
eye care services in the USA. Visionworks is a significant North
American chain and this order follows the recent material contract
for 410 Daytona in Australia and New Zealand, demonstrating the
potential that we believe Daytona offers to eye care professionals
worldwide. We reiterate our full year guidance of 1,000 to 1,200
Daytona installations for the current financial year."
Jeff Smith, Chief Medical Officer of HVHC Inc, added: "We are
excited to have the Daytona technology available in the Visionworks
locations which we believe will enhance the patient
experience."
Enquiries:
Optos plc Tel: 01383 843 300
Roy Davis, CEO
Rob Kennedy, Interim CFO
Visionworks Tel: +1 210-245-2405
Dr. Florian Safner, VP of Professional
Services
FTI Consulting Tel: 020 7831 3113
Ben Atwell / Simon Conway / Mo
Noonan
Note to Editors: Images available upon request
About Optos Plc
Optos plc has the vision to be The retina company. We aim to be
recognised as a leading provider of devices and solutions to
eyecare professionals for improved patient care. Optos' core
devices produce ultra widefield, high resolution digital images
(optomaps(R)) of approximately 82% of the retina, something no
other device is capable of doing in any one image.
Optos has a range of imaging devices that support different
customer segments and patient levels: the P200 and 200Dx devices
are concentrated on wellness screening carried out by optometrists
and ophthalmologists in primary care; the P200C devices are
designed to meet the need for more exacting clinical imaging
capabilities and standards in secondary care within the
ophthalmology market and at optometric practices that are
clinically managing a patient base with advanced ocular disease;
and the P200MA and 200Tx devices supports ophthalmologists and
retinal specialists in the medical care market.
Daytona represents the next generation of Optos ultra-widefield
retinal imaging technology, and has been scaled to accommodate
smaller office spaces while providing high resolution imaging, and
adding new auto-fluorescence capabilities. Weighing only about 25
kg, Daytona's new, ergonomic body is designed to increase patient
comfort, as well as make it easier to correctly position the eye.
In addition to the smaller, sleeker design, Daytona features an
improved user interface with its intuitive, workflow based
software. Daytona also offers "plug-n-play" installation, a modular
robust build-design to simplify product support, image review
capabilities and electronic image storage options. Daytona was
designed to allow the globalisation of the core Optos imaging
technology, giving the opportunity to offer the benefits of
optomaps(R) technology to more eyecare professionals and their
patients around the world.
The acquisition of OPKO instrumentation in October 2011 brought
the group optical coherence tomography ("OCT") diagnostic devices
and optical ultrasound scanners, used in the diagnosis and
management of eye disease and conditions. Optos' widefield retinal
imaging technology, combined with the specific data that can be
derived from OCT images, has the potential to offer
ophthalmologists and optometrists the most powerful tools for
disease diagnosis and management. The optomaps(R) images provide
enhanced clinical information which facilitates the early
detection, management and treatment of disorders and diseases
evidenced in the retina such as retinal detachments and tears,
glaucoma, diabetic retinopathy and age-related macular
degeneration. Retinal imaging can also indicate evidence of non-eye
or systemic diseases such as hypertension and certain cancers. OCT
delivers an image that shows a three dimensional, cross-sectional
view of the retina in any particular area, typically in the central
pole area of the retina around the optic nerve and macula and is
used to detect the presence of and understand the severity of
disease, determine treatment approaches and monitor post-treatment
effect.
Our expanded product range now includes ultra-widefield imaging,
OCT, visual acuity, perimetry and treatment laser products.
For more information please visit our website www.optos.com.
About HVHC, Inc and Visionworks
HVHC, Inc. is the leader of integrated vision care solutions for
the value-seeking customer, offering differentiated products and
services via its three divisions: national optical retailer
Visionworks, managed vision care provider Davis Vision, and
wholesale eyewear distributor Viva International. HVHC has more
than 8,600 employees and operates in seven countries, 40 states and
the District of Columbia. Headquartered in San Antonio, HVHC is the
largest wholly owned and operated U.S.-based optical company. Learn
more about HVHC, Inc., at www.hvhcretail.com.
Visionworks (formerly Eye Care Centers of America, Inc.) is a
leading provider of eye care services with 600 optical retail
stores in 40 states and the District of Columbia through 5 store
names that are leaders in eye care service in each of their
respective markets.
Visionworks is committed to providing their customers with an
excellent shopping experience and high quality products and service
with the best value and selection in the industry. All stores offer
designer and exclusive brand frames, lenses, sunglasses and
accessories along with leading technology in vision correction.
Visionworks' comprehensive service offerings include contact lens
dispensing, in-store labs which provide one-hour service on many
prescriptions at nearly all locations and doctors of optometry at
or next to every store providing comprehensive eye exams.
Visionworks is a wholly owned subsidiary of HVHC, Inc.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates and projections about its industry, its beliefs and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties and other factors, some
of which are beyond the Company's control, are difficult to predict
and could cause actual results to differ materially from those
expressed or forecasted in the forward-looking statements. The
Company cautions shareholders and prospective shareholders not to
place undue reliance on these forward-looking statements, which
reflect the view of the Company only as of the date of this
announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABRBDGCDGBGXI
Optos (LSE:OPTS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optos (LSE:OPTS)
Historical Stock Chart
From Apr 2023 to Apr 2024
